Reprogramming and Differentiation of iPSCORE

The 139 iPSCORE subjects [86 (link)] included members of 27 families (2–9 members/family), 7 monozygotic twin pairs, and 55 singletons (S1 Table). During recruitment of iPSCORE subjects, subject information (sex, age, family, ethnicity, and cardiac diseases) was collected. Recruitment was approved by the Institutional Review Boards of the University of California, San Diego and The Salk Institute (project no. 110776ZF). Skin biopsies were collected for each iPSCORE individual.
As previously described in detail [86 (link)–88 (link)], we reprogrammed skin fibroblast samples from 139 iPSCORE individuals using non-integrative Cytotune Sendai virus (Life Technologies) and the 149 iPSCs (7 subjects had 2 or more clones each) were shown to be pluripotent and to have high genomic integrity with no or low numbers of somatic copy-number variants (CNVs). To generate iPSC-derived cardiovascular progenitors (iPSC-CVPC) we used a small molecule differentiation protocol, which included purification of iPSC-CVPC cultures using lactate [89 (link)], and harvested iPSC-CVPC at day 25 (D25) differentiation [14 (link),85 (link)]. We obtained RNA-seq (150 bp PE) for 180 iPSC-CVPC (30 of the 149 iPSCs were differentiated two or more times). All iPSCORE iPSC-CVPC RNA-seq samples are available through dbGaP (phs000924).